🇺🇸 FDA
Pipeline program

LEO 90105

MCB 0904

Phase 2 small_molecule completed

Quick answer

LEO 90105 for Psoriasis Vulgaris is a Phase 2 program (small_molecule) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
LEO Pharma A/S
Indication
Psoriasis Vulgaris
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials